ReviewFrontiers in oncology2014
Side effects of yttrium-90 radioembolization.
Review in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Selective internal radiation therapy of metastatic breast cancer to the liver: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Radioembolization: Is Prophylactic Embolization of Hepaticoenteric Arteries Necessary? A Systematic Review.Cardiovascular and interventional radiology · 2016Pooled it
- Quality of life in patients with liver tumors treated with holmium-166 radioembolization.Clinical & experimental metastasis · 2020Trial
- Glass versus resin microspheres in ⁹⁰Y radioembolization for hepatocellular carcinoma: toxicity patterns under uniform voxel-based dosimetry.Annals of nuclear medicine · 2026Article
- Sequential Yttrium-90 radioembolization integrated with multimodal therapy for platinum-resistant ovarian cancer liver metastases.Gynecologic oncology reports · 2026Article
- Radioprotectant-loaded visualizable cationic radioactive microspheres: Reduced hepatic tissue damage and intra/postoperative imaging during TARE.Materials today. Bio · 2026Article
- Multimodal imaging techniques in Yttrium-90 radioembolization for hepatocellular carcinoma: a modality-oriented clinical review.Frontiers in oncology · 2026Review
- Article
- Association Between Discharge Medications and Oncologic Post-Embolization-Syndrome-Related Outcomes.Cancer medicine · 2025Article
- Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma.European journal of nuclear medicine and molecular imaging · 2025Article
- Safety and efficacy of transarterial therapies for pancreatic acinar cell carcinoma metastases.Clinical imaging · 2025Article
- Current Research in Drug-Free Cancer Therapies.Bioengineering (Basel, Switzerland) · 2025Review
- Review
- Diagnosis and management of radiation cholecystitis as a complication of Y90 radioembolization for hepatocellular carcinoma.Radiology case reports · 2024Article
- Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy.Cancer research communications · 2024Article
- MIDOS: a novel stochastic model towards a treatment planning system for microsphere dosimetry in liver tumors.European journal of nuclear medicine and molecular imaging · 2024Article
- Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients.Journal of the Chinese Medical Association : JCMA · 2024Article
- MIRD Pamphlet No. 29: MIRDy90-AJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Quantitative differences in volumetric calculations for radiation dosimetry in segmental Y90 treatment planning using hybrid angiography-CT compared with anatomic segmentation.The British journal of radiology · 2024Article
- Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma.Seminars in interventional radiology · 2024Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited therapeutic options are available for hepatic malignancies. Image guided targeted therapies have established their role in management of primary and secondary hepatic malignancies. Radioembolization with yttrium-90 ((90)Y) microspheres is safe and efficacious for treatment of hepatic malignancies. The tumoricidal effect of radioembolization is predominantly due to radioactivity and not ischemia. This article will present a comprehensive review of the side effects that have been associated with radioembolization using (90)Y microspheres. Some of the described side effects are associated with all transarterial procedures. Side effects specific to radioembolization will also be discussed in detail. Methods to decrease the incidence of these potential side effects will also be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.